REMARKS

This paper is filed concurrently with the application papers requesting filing and immediate examination of a United States national application based on international application no. PCT/US2004/000892, January 13, 2004, claiming priority to US provisional application 60/440,812 filed January 17, 2003. Please enter the foregoing amendments prior to calculation of the filing fee and prior to examination on the merits.

The first paragraph of the specification has been amended herein to provide updated information regarding cross-reference to related applications under 37 C.F.R. § 1.78.

Applicant has amended Claim 1 (positions 5, 8, and 14) and paragraphs 24, 27, and 33 of the specification to delete the initial reference to "Inc" (indoline-2-carboxylic acid) and include it within the listing of D- or L- amino acids. Support for the amendment is apparent from the original claim and paragraphs as well as in original Claim 1 and paragraphs 24, 27, and 33 of the priority document, US provisional application 60/440,812.

Applicant has amended Claim 1 (position 22) and paragraph 41 of the specification to include the amino acid alanine (Ala). Support for the amendment can be found on page 13, paragraph 132 of the international publication WO 2004/066966 as well as paragraph 131 of the priority document, US provisional application 60/440,812.

Applicant has amended Claim 1 (position 23) and paragraph 42 of the specification to include the amino acid tryptophan (Trp). Support for the amendment can be found on page 13, paragraph 133 of the international publication WO 2004/066966 as well as paragraph 132 of the priority document, US provisional application 60/440,812.

Applicant has amended Claim 1 (position 25) and paragraph 44 of the specification to delete the duplicate reference to α-aminoisobutyric acid (Aib) and insert therefor substituted amino acid "Apc". Support for the amendment can be found on page 12, paragraph 99 of the international publication WO 2004/066966 as well as in Claim 1 and paragraph 43 of the priority document, US provisional application 60/440,812.

Applicant has amended Claim 1 and paragraph 66 of the specification to insert amino acid position "$\underline{A^{34}}$" between A^{33} and A^{35}. Support for the amendment can be found on page 9, paragraph 53 of the international publication WO 2004/066966 as well as in Claim 1 and paragraph 52 of the priority document, US provisional application 60/440,812.

Applicant has amended Claims 9 and 12, as well as paragraphs 393 and 426 of the specification to include the sequence Ac-(A6c^{24})hPYY(24-36)NH_2 (SEQ ID NO. 64). Support for the

amendment can be found throughout the application, see, e.g., paragraph 305 of the international publication WO 2004/066966.

Last, Applicant requests amendment to the table found on page 37 of the application. After filing, Applicant noticed that the purity data from compounds 26, 27, and 28 had inadvertently been switched: the purity value set forth for compound 26 (97.5) was actually the reading for compound 27; the purity value set forth for compound 27 (96.3) was actually the reading for compound 28; and the purity value set forth for compound 28 (98.8) was actually the reading for compound 26.

The remaining amendments to the claims are clerical in nature, e.g., they either eliminate improper multiple dependencies or clarify the claim language to aid examination without substantively changing the claim. The claims are thus presented in proper form for review in the USPTO. It is not the intention of the Applicants to abandon any of the inventive subject matter disclosed in the application as originally filed. Support for these amendments is apparent in the original claims 1-28, and no new matter is added thereby.

A check (No. 6462) in the amount of $1,000.00 to cover the national stage filing fees accompanies these papers, and the fees are calculated taking the foregoing amendments into account, since the amendments eliminate some multiple dependencies from the claims. No additional fees are believed to be due; however, the Commissioner is specifically authorized to charge any additional fees deemed to be necessary in connection with the filing of this paper or any of the accompanying papers, or to charge other fees necessary to complete this US filing to Deposit Account 50-0268.

Entry of the foregoing amendments and examination of the claims as amended are requested.

Respectfully submitted,



Leon R. Yankwich, Reg. No. 30,237
Michael R. Wesolowski, Reg. No. 50,944
Attorneys for Applicant

Direct all correspondence to:
Brian R. Morrill, Esq.
Biomeasure, Incorporated
27 Maple Street
Milford, MA 01757-3650
telephone: (508) 478-0144
telecopier: (508) 473-3531

IN THE CLAIMS

COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS
(Currently amended claims showing deletions by ~~strikethrough~~ and additions by underlining)

This listing of claims will replace all prior versions and listings of the claims in the application.

Listing of Claims:

1. (currently amended) A compound according to formula (I):

$(R^2,R^3)A^3$-A^4-A^5-A^6-A^7-A^8-A^9-A^{10}-A^{11}-A^{12}-A^{13}-A^{14}-A^{15}-A^{16}-A^{17}-A^{18}-A^{19}-A^{20}-A^{21}-A^{22}-A^{23}-A^{24}-A^{25}-A^{26}-A^{27}-A^{28}- A^{29}-A^{30}-A^{31}-A^{32}-A^{33}-A^{34}-A^{35}-A^{36}-R^1

(I)

wherein:

A^3 is Acc, Act, or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Ile, Leu, Nle, Tle, hLeu, Cha, Val, Ala, Nva, and Abu, or the N-methylated variant of Acc, Act, or Aib, or of said D- or L- amino acid, or is deleted;

A^4 is Aib, Acc, or Apc, or a D- or L- amino acid selected from the list of amino acids consisting of Lys, Arg, hArg, Orn, Dab, Dap, and HN-CH($(CH_2)_n$-N(R^4R^5))-C(O), or the N-methylated variant of Aib, Acc, or Apc, or of said D- or L- amino acid, or is deleted;

A^5 is ~~Inc, or~~ a D- or L- amino acid selected from the list of amino acids consisting of Pro, Thz, Dmt, Dhp, Ktp, 4Hyp, 3Hyp, Pip, Tic, Inc and Oic, or the N-methylated variant of Inc or of said D- or L- amino acid, or is deleted;

A^6 is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Glu, Asp, Gln, Asn, Lys, Arg, Orn, Dab, Dap, and hArg, or the N-methylated variant of Acc or Aib, or of said D- or L- amino acid, or is deleted;

A^7 is Acc, Act, Aib, Apc, or Gly, or a D- or L- amino acid selected from the list of amino acids consisting of Ala, Abu, Val, and Nva, or the N-methylated variant of Acc, Act, Aib, Apc, or Gly, or of said D- or L- amino acid, or is deleted;

A^8 is ~~Inc or~~ a D- or L- amino acid selected from the list of amino acids consisting of Pro, Thz, Dmt, Dhp, Ktp, 4Hyp, 3Hyp, Pip, Tic, Inc and Oic, or the N-methylated variant of Inc or of said D- or L- amino acid, or is deleted;

A^9 is Acc, Aib, or Gly, or D- or L- Ala, or the N-methylated variant of Acc, Aib, Gly, or D- or L- Ala, or is deleted;

A^{10} is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Glu, Asp, Gln, and Asn, or the N-methylated variant of Acc or Aib, or of said D- or L- amino acid, or is deleted;

A^{11} is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Asp, Glu, Gln, and Asn, or the N-methylated variant of Acc or Aib, or of said D- or L- amino acid, or is deleted;

A^{12} is Acc, Act, Aib, Apc, or Gly, or a D- or L- amino acid selected from the list of amino acids consisting of Ala, Abu, Val, and Nva, or the N-methylated variant of Acc, Act, Aib, Apc, or Gly, or of said D- or L- amino acid, or is deleted;

A^{13} is Acc, Aib, or Act, or a D- or L- amino acid selected from the list of amino acids consisting of Ser, Thr, Ala, Abu, and Val, or the N-methylated variant of Acc, Aib, or Act, or of said D- or L- amino acid, or is deleted;

A^{14} is ~~Inc or~~ a D- or L- amino acid selected from the list of amino acids consisting of Pro, Thz, Dmt, Dhp, Ktp, 4Hyp, 3Hyp, Pip, Tic, Inc and Oic, or the N-methylated variant of Inc or of said D- or L- amino acid, or is deleted;

A^{15} is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Glu, Asp, Gln, and Asn, or the N-methylated variant of Acc or Aib, or of said D- or L- amino acid, or is deleted;

A^{16} is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Glu, Asp, Gln, and Asn, or the N-methylated variant of Acc or Aib, or of said D- or L- amino acid, or is deleted;

A^{17} is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Leu, Ile, Nle, Tle, hLeu, Cha, Val, Ala, Nva, Abu, and Phe, or the N-methylated variant of Acc or Aib, or of said D- or L- amino acid, or is deleted;

A^{18} is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Asn, Gln, Glu, and Asp, or the N-methylated variant of Acc or Aib, or of said D- or L- amino acid, or is deleted;

A^{19} is Acc, Aib, or Apc, or a D- or L- amino acid selected from the list of amino acids consisting of Arg, hArg, Lys, Orn, Dab, Dap, and $HN\text{-}CH((CH_2)_n\text{-}N(R^4R^5))\text{-}C(O)$, or the N-methylated variant of Acc, Aib, or Apc, or of said D- or L- amino acid, or is deleted;

A^{20} is Acc or Aic, or a D- or L- amino acid selected from the list of amino acids consisting of Tyr, Phe, hPhe, 2Thi, 3Thi, Taz, 2Fua, Trp, 2Nal, 1Nal, Cha, 2Pal, 3Pal, 4Pal, and (X^1,X^2,X^3,X^4,X^5)Phe, or the N-methylated variant of Acc or Aic, or of said D- or L- amino acid, or is deleted;

A^{21} is Acc or Aic, or a D- or L- amino acid selected from the list of amino acids consisting of Tyr, Phe, hPhe, 2Thi, 3Thi, Taz, 2Fua, Trp, 2Nal, 1Nal, Cha, 2Pal, 3Pal, 4Pal, and (X^1,X^2,X^3,X^4,X^5)Phe, or the N-methylated variant of Acc or Aic, or of said D- or L- amino acid, or is deleted;

A^{22} is Acc, Act, Aib, Apc, or Gly, or a D- or L- amino acid selected from the list of amino acids consisting of Ala, Aib, Abu, Val, and Nva, or the N-methylated variant of Ala, Acc, Act, Aib, Apc, or Gly, or of said D- or L- amino acid, or is deleted;

A^{23} is Acc, Act, or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Trp, Ser, Thr, Ala, Abu, and Val, or the N-methylated variant of Acc, Act, or Aib, or of said D- or L- amino acid, or is deleted;

A^{24} is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Leu, Ile, Nle, Tle, hLeu, Cha, Val, Ala, Nva, Abu, Trp, and Phe, or the N-methylated variant of Acc or Aib, or of said D- or L- amino acid, or is deleted;

A^{25} is Acc, Aib, or ~~Aib~~Apc, or a D- or L- amino acid selected from the list of amino acids consisting of Arg, hArg, Lys, Orn, Dab, Dap, Aib, and HN-CH($(CH_2)_n$-N(R^4R^5))-C(O), or the N-methylated variant of Acc, Aib, or ~~Aib~~Apc, or of said D- or L- amino acid, or is deleted;

A^{26} is Acc, Aib, or Apc, or a D- or L- amino acid selected from the list of amino acids consisting of His, 2Pal, 3Pal, 4Pal, Taz, 2Thi, 3Thi, 2Fua, HN-CH($(CH_2)_n$-N(R^4R^5))-C(O), and $(X^1,X^2,X^3,X^4,X^5$-)Phe, or the N-methylated variant of Acc, Aib, or Apc, or of said D- or L- amino acid, or is deleted;

A^{27} is Acc or Aic, or a D- or L- amino acid selected from the list of amino acids consisting of Tyr, Phe, hPhe, 2Thi, 3Thi, Taz, 2Fua, Trp, 2Nal, 1Nal, Cha, 2Pal, 3Pal, 4Pal, and (X^1,X^2,X^3,X^4,X^5)Phe, or the N-methylated variant of Acc or Aic or of said D- or L- amino acid;

A^{28} is Acc or Aib, a D- or L- amino acid selected from the list of amino acids consisting of Leu, Ile, Nle, Tle, hLeu, Trp, Cha, Val, Ala, Nva, Abu, and Phe, or the N-methylated variant of Acc or Aib, or of said D- or L- amino acid;

A^{29} is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Asn, Gln, Glu, Asp, and Trp, or the N-methylated variant of Acc or Aib, or of said D- or L- amino acid;

A^{30} is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Leu, Ile, Nle, Tle, hLeu, Trp, Cha, Val, Ala, Nva, Abu, and Phe or the N-methylated variant of Acc or Aib, or of said D- or L- amino acid;

A^{31} is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Val, Leu, Ile, Nle, Tle, hLeu, Cha, Ala, Nva, Abu, Trp, and Phe, or the N-methylated variant of Acc or Aib, or of said D- or L- amino acid;

A^{32} is Acc, Act, or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Thr, Ser, Ala, Abu, Trp, DTrp, and Val, or the N-methylated variant of Acc, Act, or Aib, or of said D- or L- amino acid;

A^{33} is Acc, Aib, or Apc, or a D- or L- amino acid selected from the list of amino acids consisting of Arg, hArg, Lys, Orn, Dab, Dap, and HN-CH($(CH_2)_n$-N(R^4R^5))-C(O), or the N-methylated variant of Acc, Aib, or Apc, or of said D- or L- amino acid;

A^{34} is Acc, Aib, or Apc, or a D- or L- amino acid selected from the list of amino acids consisting of Gln, Asn, Glu, Asp, or the N-methylated variant of Acc, Aib, or Apc, or of said D- or L-amino acid;

A^{35} is Acc, Aib, or Apc, or a D- or L- amino acid selected from the list of amino acids consisting of Arg, hArg, Lys, Orn, Dab, Dap, and HN-CH($(CH_2)_n$-N(R^4R^5))-C(O), or the N-methylated variant of Acc, Aib, or Apc, or of said D- or L- amino acid;

A^{36} is Acc, Aic or Apc, or a D- or L- amino acid selected from the list of amino acids consisting of Tyr, Phe, hPhe, 2Thi, 3Thi, Taz, 2Fua, Trp, 2Nal, 1Nal, Cha, 2Pal, 3Pal, 4Pal, and (X^1,X^2,X^3,X^4,X^5)Phe, or the N-methylated variant of Acc, Aic, or Apc, or of said D- or L- amino acid;

R^1 is OH or NH_2, (C_1-C_{30})alkoxy, or NH-X^6-CH_2-Z^0, wherein X^6 is a (C_1-C_{12})hydrocarbon moiety, and Z^0 is -H, -OH, -CO_2H or -C(O)NH_2;

R^2 and R^3 each is, independently for each occurrence, selected from the group consisting of -H, (C_1-C_{30})alkyl, (C_1-C_{30})heteroalkyl, (C_1-C_{30})acyl, (C_2-C_{30})alkenyl, (C_2-C_{30})alkynyl, aryl(C_1-C_{30})alkyl, aryl(C_1-C_{30})acyl, substituted (C_1-C_{30})alkyl, substituted (C_1-C_{30})heteroalkyl, substituted (C_2-C_{30})acyl, substituted (C_2-C_{30})alkenyl, substituted (C_2-C_{30})alkynyl, substituted aryl(C_1-C_{30})alkyl, and substituted aryl(C_1-C_{30})acyl,

provided that when R^2 is (C_1-C_{30})acyl, aryl(C_1-C_{30})acyl, substituted (C_2-C_{30})acyl, or substituted aryl(C_1-C_{30})acyl, R^3 is -H, (C_1-C_{30})alkyl, (C_1-C_{30})heteroalkyl, (C_2-C_{30})alkenyl, (C_2-C_{30})alkynyl, aryl(C_1-C_{30})alkyl, substituted (C_1-C_{30})alkyl, substituted (C_1-C_{30})heteroalkyl, substituted (C_2-C_{30})alkenyl, substituted (C_2-C_{30})alkynyl, or substituted aryl(C_1-C_{30})alkyl;

R^4 and R^5 each is, independently for each occurrence, selected from the group consisting of -H, (C_1-C_{40})alkyl, (C_2-C_{40})acyl, (C_1-C_{30})alkylsulfonyl, and -C(NH)NH_2,

provided that when R^4 is (C_1-C_{40})acyl, (C_1-C_{30})alkylsulfonyl, or -C(NH)NH_2, then R^5 is -H or (C_1-C_{40})alkyl;

n is, independently for each occurrence, 1, 2, 3, 4 or 5; and

X^1, X^2, X^3, X^4, and X^5 each is, independently for each occurrence, selected from the group consisting of -H, -F, -Cl, -Br, -I, (C_1-C_{10})alkyl, substituted (C_1-C_{10})alkyl, aryl, substituted aryl, -OH, $-NH_2$, $-NO_2$, and -CN;

provided that:

(a) said peptide comprises at least one amino acid selected from the group consisting of:

(i) Acc at A^3, A^6, A^7, A^9, A^{10}, A^{11}, A^{12}, A^{15}, A^{16}, A^{17}, A^{18}, A^{20}, A^{21}, A^{22}, A^{24}, A^{27}, A^{28}, A^{29}, A^{30}, A^{31}, A^{32}, or A^{34};

(ii) Act at A^3, A^7, A^{12}, A^{13}, A^{22}, A^{23}, or A^{32};

(iii) Apc at A^4, A^7, A^{12}, A^{19}, A^{22}, A^{25}, A^{26}, A^{33}, A^{34}, A^{35}, or A^{36};

(iv) Aib at A^6, A^7, A^9, A^{10}, A^{11}, A^{12}, A^{13}, A^{15}, A^{16}; A^{18}, A^{22}, A^{29}, or A^{32};

(v) Thz, Dmt, Dhp, Ktp, or Tic at A^5, A^8, or A^{14};

(vi) (3,4,5-F)Phe or (2,3,4,5,6-F)Phe at A^{20}, A^{21}, A^{26}, A^{27}, or A^{36};

(vii) 2Fua at A^{20}, A^{21}, A^{26}, or A^{27};

(viii) Taz at A^{20}, A^{21}, or A^{26}; and

(ix) 2Pal, 3Pal, 4Pal, 2Thi or 3Thi at A^{26};

(b) if A^3 - A^{21} are deleted and (i) A^{22} is Aib or (ii) A^{36} is (3,4,5-F)Phe or (2,3,4,5,6-F)Phe, then A^{27} is not 2Thi, Trp, 2Nal, or (X^1,X^2,X^3,X^4,X^5)Phe, wherein X^1 is *p*-chloro and X^2, X^3, X^4 and X^5 each is -H; and

(c) each amino acid A^m of formula (I) may be deleted only if A^{m-1} is deleted, wherein m is an integer ranging in value from 4 - 26, inclusive;

or a pharmaceutically acceptable salt thereof.

2. (original) A compound according to claim 1, wherein:

A^3 is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Ile, Leu, Nle, Tle, hLeu, Cha, Val, Ala, Nva, and Abu, or is deleted;

A^4 is Acc, Aib, or Apc, or a D- or L- amino acid selected from the list of amino acids consisting of Lys, Arg, hArg, Orn, Dab, Dap, and HN-CH($(CH_2)_n$-N(R^4R^5))-C(O), or is deleted;

A^5 is Inc or a D- or L- amino acid selected from the list of amino acids consisting of Pro, Thz, Dmt, Dhp, Ktp, 4Hyp, 3Hyp, Pip, Tic, and Oic, or is deleted;

A^6 is Acc or a D- or L- amino acid selected from the list of amino acids consisting of Glu, Asp, Gln, Asn, Lys, Arg, Orn, Dab, Dap, and hArg, or is deleted;

A^7 is Acc, Act, Aib, Apc, or Gly, or a D- or L- amino acid selected from the list of amino acids consisting of Ala, Abu, Val, and Nva, or is deleted;

A^8 is Inc or a D- or L- amino acid selected from the list of amino acids consisting of Pro, Thz, Dmt, Dhp, Ktp, 4Hyp, 3Hyp, Pip, Tic, and Oic, or is deleted;

A^9 is Acc, Aib, or Gly or D- or L- Ala, or is deleted;

A^{10} is Acc or a D- or L- amino acid selected from the list of amino acids consisting of Glu, Asp, Gln, and Asn, or is deleted;

A^{11} is Acc or a D- or L- amino acid selected from the list of amino acids consisting of Asp, Glu, Gln, and Asn, or is deleted;

A^{12} is Acc, Act, Aib, or Apc, or a D- or L- amino acid selected from the list of amino acids consisting of Ala, Gly, Abu, Val, and Nva, or is deleted;

A^{13} is Acc, Act, or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Ser, Thr, Ala, Abu, and Val, or is deleted;

A^{14} is Inc or a D- or L- amino acid selected from the list of amino acids consisting of Pro, Thz, Dmt, Dhp, Ktp, 4Hyp, 3Hyp, Pip, Tic, and Oic, or is deleted;

A^{15} is Acc or a D- or L- amino acid selected from the list of amino acids consisting of Glu, Asp, Gln, and Asn, or is deleted;

A^{16} is Acc or a D- or L- amino acid selected from the list of amino acids consisting of Glu, Asp, Gln, and Asn, or is deleted;

A^{17} is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Leu, Ile, Nle, Tle, hLeu, Cha, Val, Ala, Nva, Abu, and Phe, or is deleted;

A^{18} is Aib or Acc, or a D- or L- amino acid selected from the list of amino acids consisting of Asn, Gln, Glu, and Asp, or is deleted;

A^{19} is Acc, Aib, or Apc, or a D- or L- amino acid selected from the list of amino acids consisting of Arg, hArg, Lys, Orn, Dab, Dap, and HN-CH($(CH_2)_n$-N(R^4R^5))-C(O), or is deleted;

A^{20} is Acc or Aic, a D- or L- amino acid selected from the list of amino acids consisting of Tyr, Phe, hPhe, 2Thi, 3Thi, Taz, 2Fua, Trp, 2Nal, 1Nal, Cha, 2Pal, 3Pal, 4Pal, and (X^1,X^2,X^3,X^4,X^5)Phe, or is deleted;

A^{21} is Acc or Aic, or a D- or L- amino acid selected from the list of amino acids consisting of Tyr, Phe, hPhe, 2Thi, 3Thi, Taz, 2Fua, Trp, 2Nal, 1Nal, Cha, 2Pal, 3Pal, 4Pal, and (X^1,X^2,X^3,X^4,X^5)Phe, or is deleted;

A^{22} is Acc, Act, Aib, Apc, or Gly, or a D- or L- amino acid selected from the list of amino acids consisting of Ala, Abu, Val, and Nva, or is deleted;

A^{23} is Acc, Act, or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Ser, Thr, Ala, Abu, and Val, or is deleted;

A^{24} is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Leu, Ile, Nle, Tle, hLeu, Cha, Val, Ala, Nva, Abu, Trp, and Phe, or is deleted;

A^{25} is Acc, Aib, or Apc, or a D- or L- amino acid selected from the list of amino acids consisting of Arg, hArg, Lys, Orn, Dab, Dap, and HN-CH($(CH_2)_n$-N(R^4R^5))-C(O), or is deleted

A^{26} is Acc, Aib, or Apc, or a D- or L- amino acid selected from the list of amino acids consisting of His, 2Pal, 3Pal, 4Pal, Taz, 2Thi, 3Thi, 2Fua, HN-CH($(CH_2)_n$-N(R^4R^5))-C(O), and (X^1,X^2,X^3,X^4,X^5-)Phe, or is deleted;

A^{27} is Acc or Aic, or a D- or L- amino acid selected from the list of amino acids consisting of Tyr, Phe, hPhe, 2Thi, 3Thi, Taz, 2Fua, Trp, 2Nal, 1Nal, Cha, 2Pal, 3Pal, 4Pal, and (X^1,X^2,X^3,X^4,X^5)Phe;

A^{28} is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Leu, Ile, Nle, Tle, hLeu, Trp, Cha, Val, Ala, Nva, Abu, and Phe;

A^{29} is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Asn, Gln, Glu, Asp, and Trp;

A^{30} is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Leu, Ile, Nle, Tle, hLeu, Trp, Cha, Val, Ala, Nva, Abu, and Phe;

A^{31} is Acc or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Val, Leu, Ile, Nle, Tle, hLeu, Cha, Ala, Nva, Abu, Trp, and Phe;

A^{32} is Acc, Act, or Aib, or a D- or L- amino acid selected from the list of amino acids consisting of Thr, Ser, Ala, Abu, Trp, and Val;

A^{33} is Acc, Aib, or Apc, or a D- or L- amino acid selected from the list of amino acids consisting of Arg, hArg, Lys, Orn, Dab, Dap, and HN-CH($(CH_2)_n$-N(R^4R^5))-C(O);

A^{34} is Acc, Aib, Apc, or Glu, or a D- or L- amino acid selected from the list of amino acids consisting of Gln, Asn, and Asp;

A^{35} is Acc, Aib, or Apc, or a D- or L- amino acid selected from the list of amino acids consisting of Arg, hArg, Lys, Orn, Dab, Dap, and HN-CH($(CH_2)_n$-N(R^4R^5))-C(O); and

A^{36} is Acc, Aic, or Apc, or a D- or L- amino acid selected from the list of amino acids consisting of Tyr, Phe, hPhe, 2Thi, 3Thi, Taz, 2Fua, Trp, 2Nal, 1Nal, Cha, 2Pal, 3Pal, 4Pal, and (X^1,X^2,X^3,X^4,X^5)Phe;

or a pharmaceutically acceptable salt thereof.

3. (original) A compound according to claim 2, wherein:

A^3 is Ile, Leu, Nle, Tle, hLeu, Cha, Val, Ala, Nva, Abu, Acc, or Aib, or is deleted;

A^4 is Lys, Arg, hArg, Orn, Dab, Dap, Apc, Aib, Acc, or HN-CH($(CH_2)_n$-N(R^4R^5))-C(O), or is deleted;

A^5 is Pro, Thz, Dmt, Dhp, Ktp, 4Hyp, 3Hyp, Pip, Tic, Oic, or Inc, or is deleted;

A^6 is Glu, Asp, Gln, Asn, Lys, Arg, Orn, Dab, Dap, hArg, or Acc, or is deleted;

A^7 is Ala, Aib, Gly, Abu, Val, Nva, Apc, Act, or Acc, or is deleted;

A^8 is Pro, Thz, Dmt, Dhp, Ktp, 4Hyp, 3Hyp, Pip, Tic, Oic, or Inc, or is deleted;

A^9 is Gly, Ala, Aib, or Acc, or is deleted;

A^{10} is Glu, Asp, Gln, Asn, or Acc, or is deleted;

A^{11} is Asp, Glu, Gln, Asn, or Acc, or is deleted;

A^{12} is Ala, Aib, Gly, Abu, Val, Nva, Apc, Act, or Acc, or is deleted;

A^{13} is Ser, Thr, Aib, Act, Ala, Acc, Abu, or Val, or is deleted;

A^{14} is Pro, Thz, Dmt, Dhp, Ktp, 4Hyp, 3Hyp, Pip, Tic, Oic, or Inc, or is deleted;

A^{15} is Glu, Asp, Gln, Asn, or Acc, or is deleted;

A^{16} is Glu, Asp, Gln, Asn, or Acc, or is deleted;

A^{17} is Leu, Ile, Nle, Tle, hLeu, Cha, Val, Ala, Nva, Abu, Acc, Aib, or Phe, or is deleted;

A^{18} is Asn, Gln, Glu, Asp, Aib, or Acc, or is deleted;

A^{19} is Arg, hArg, Lys, Orn, Dab, Dap, Apc, Aib, Acc, or HN-CH($(CH_2)_n$-N(R^4R^5))-C(O), or is deleted;

A^{20} is Tyr, Phe, hPhe, 2Thi, 3Thi, Taz, 2Fua, Trp, 2Nal, 1Nal, Cha, 2Pal, 3Pal, 4Pal, (X^1,X^2,X^3,X^4,X^5)Phe, Acc, or Aic, or is deleted;

A^{21} is Tyr, Phe, hPhe, 2Thi, 3Thi, Taz, 2Fua, Trp, 2Nal, 1Nal, Cha, 2Pal, 3Pal, 4Pal, (X^1,X^2,X^3,X^4,X^5)Phe, Acc, or Aic, or is deleted;

A^{22} is Ala, Aib, Gly, Abu, Val, Nva, Apc, Act, Acc, or N-Me-Ala, or is deleted;

A^{23} is Ser, Thr, Aib, Act, Ala, Acc, Abu, Val, or DTrp, or is deleted;

A^{24} is Leu, Ile, Nle, Tle, hLeu, Cha, Val, Ala, Nva, Abu, Acc, Aib, Trp, or Phe, or is deleted;

A^{25} is Arg, hArg, Lys, Orn, Dab, Dap, Apc, Aib, HN-CH($(CH_2)_n$-N(R^4R^5))-C(O), or Acc, or is deleted;

A^{26} is His, 2Pal, D2Pal, 3Pal, 4Pal, Taz, 2Thi, 3Thi, 2Fua, Apc, Aib, Acc, HN-CH($(CH_2)_n$-N(R^4R^5))-C(O), or (X^1,X^2,X^3,X^4,X^5-)Phe, or is deleted;

A^{27} is Tyr, Phe, hPhe, 2Thi, 3Thi, Taz, 2Fua, Trp, 2Nal, 1Nal, Cha, 2Pal, 3Pal, 4Pal, (X^1,X^2,X^3,X^4,X^5)Phe, Acc, or Aic;

A^{28} is Leu, Ile, Nle, Tle, hLeu, Trp, Cha, Val, Ala, Nva, Abu, Acc, Aib, or Phe;

A^{29} is Asn, Gln, Glu, Asp, Acc, Trp, or Aib;

A^{30} is Leu, Ile, Nle, Tle, hLeu, Trp, Cha, Val, Ala, Nva, Abu, Acc, Aib, or Phe;

A^{31} is Val, Leu, Ile, Nle, Tle, hLeu, Cha, Ala, Nva, Abu, Acc, Aib, Trp, or Phe;

A^{32} is Thr, Ser, Aib, Act, Ala, Acc, Abu, Trp, DTrp, or Val;

A^{33} is Arg, hArg, Lys, Orn, Dab, Dap, Apc, Aib, HN-CH($(CH_2)_n$-N(R^4R^5))-C(O), or Acc;

A^{34} is Gln, Asn, Glu, Asp, Acc, Aib, or Apc;

A^{35} is Arg, hArg, Lys, Orn, Dab, Dap, Apc, Aib, HN-CH($(CH_2)_n$-N(R^4R^5))-C(O), or Acc; and

A^{36} is Tyr, Phe, hPhe, 2Thi, 3Thi, Taz, 2Fua, Trp, 2Nal, 1Nal, Cha, 2Pal, 3Pal, 4Pal, (X^1,X^2,X^3,X^4,X^5)Phe, Acc, Aic, or Apc; or

a pharmaceutically acceptable salt thereof.

4. (original) A compound according to claim 3, wherein:

A^3 is Ile, Leu, Nle, Val, Acc, or Aib, or is deleted;

A^4 is Lys, Arg, hArg, Orn, or Apc, or is deleted;

A^5 is Pro, Thz, Dmt, 4Hyp, or 3Hyp, or is deleted;

A^6 is Glu, Asp, Gln, or Acc, or is deleted;

A^7 is Ala, Aib, Abu, Act, or Acc, or is deleted;

A^8 is Pro, Thz, Dmt, 4Hyp, or 3Hyp, or is deleted;

A^9 is Gly, Aib, or Acc, or is deleted;

A^{10} is Glu, Asp, Gln, or Acc or is deleted;

A^{11} is Asp, Glu, Asn, or Acc or is deleted;

A^{12} is Ala, Aib, Act, or Acc, or is deleted;

A^{13} is Ser, Thr, Aib, Act, or Acc, or is deleted;

A^{14} is Pro, Thz, Dmt, 4Hyp, or 3Hyp, or is deleted;

A^{15} is Glu, Asp, Gln, or Acc, or is deleted;

A^{16} is Glu, Asp, Gln, or Acc or is deleted;

A^{17} is Leu, Ile, Nle, Val, Acc, or Aib, or is deleted;

A^{18} is Asn, Gln, Asp, Aib, or Acc or is deleted;

A^{19} is Arg, hArg, Lys, or Apc, or is deleted;

A^{20} is Tyr, Phe, 2Pal, 3Pal, 4Pal, (X^1,X^2,X^3,X^4,X^5)Phe, or Acc, or is deleted;

A^{21} is Tyr, Phe, 2Pal, 3Pal, 4Pal, (X^1,X^2,X^3,X^4,X^5)Phe, or Acc, or is deleted;

A^{22} is Ala, Aib, Abu, or Acc, or is deleted;

A^{23} is Ser, Thr, Aib, Act, or Ala, or is deleted;

A^{24} is Leu, Ile, Nle, Val, Acc, or Aib, or is deleted;

A^{25} is Arg, hArg, Lys, or Apc, or is deleted;

A^{26} is His, 2Pal, D2Pal, 3Pal, 4Pal, Taz, 2Thi, 3Thi, Apc, or (X^1,X^2,X^3,X^4,X^5-)Phe, or is deleted;

A^{27} is Tyr, Phe, 2Pal, 3Pal, 4Pal, (X^1,X^2,X^3,X^4,X^5)Phe or Acc;

A^{28} is Leu, Ile, Nle, Val, Acc or Aib;

A^{29} is Asn, Gln, Asp, Acc or Aib;

A^{30} is Leu, Ile, Nle, Val, Acc or Aib;

A^{31} is Val, Leu, Ile, Ala, Acc or Aib;

A^{32} is Thr, Ser, Aib, Act or Acc;

A^{33} is Arg, hArg, Lys or Apc;

A^{34} is Gln, Asn, Glu, Aib or Apc;

A^{35} is Arg, hArg, Lys or Apc; and

A^{36} is Tyr, Phe, 2Pal, 3Pal, 4Pal, (X^1,X^2,X^3,X^4,X^5)Phe or Apc;

or a pharmaceutically acceptable salt thereof.

5. (original) A compound according to claim 4, wherein:

A^3 is Ile or Acc, or is deleted;

A^4 is Lys or Apc, or is deleted;

A^5 is Pro or is deleted;

A^6 is Glu or Acc, or is deleted;

A^7 is Ala, Act, or Acc, or is deleted;

A^8 is Pro or is deleted;

A^9 is Gly or Acc, or is deleted;

A^{10} is Glu or Acc, or is deleted;

A^{11} is Asp or Acc, or is deleted;

A^{12} is Ala, Act, or Acc, or is deleted;

A^{13} is Ser, Act, or Acc, or is deleted;

A^{14} is Pro or is deleted;

A^{15} is Glu or Acc, or is deleted;

A^{16} is Glu or Acc, or is deleted;

A^{17} is Leu or Acc, or is deleted;

A^{18} is Asn or Acc, or is deleted;

A^{19} is Arg or Apc, or is deleted;

A^{20} is Tyr, (X^1,X^2,X^3,X^4,X^5)Phe, or Acc, or is deleted;

A^{21} is Tyr, (X^1,X^2,X^3,X^4,X^5)Phe, or Acc, or is deleted;

A^{22} is Ala, Aib, or Acc, or is deleted;

A^{23} is Ser or Act, or is deleted;

A^{24} is Leu or Acc, or is deleted;

A^{25} is Arg or Apc, or is deleted;

A^{26} is His, 2Pal, D2Pal, 3Pal, 4Pal, Taz, Apc, or $(X^1,X^2,X^3,X^4,X^5$-)Phe, or is deleted;

A^{27} is Tyr, (X^1,X^2,X^3,X^4,X^5)Phe, or Acc;

A^{28} is Leu, or Acc;

A^{29} is Asn or Acc;

A^{30} is Leu or Acc;

A^{31} is Val, Leu or Acc;

A^{32} is Thr, Act, or Acc;

A^{33} is Arg or Apc;

A^{34} is Gln or Apc;

A^{35} is Arg or Apc; and

A^{36} is Tyr, (X^1,X^2,X^3,X^4,X^5)Phe, or Apc;

or a pharmaceutically acceptable salt thereof.

6. (original) A compound according to claim 5, wherein:

Acc is, independently for each occurrence, A5c or A6c; and

(X^1,X^2,X^3,X^4,X^5)Phe is, independently for each occurrence, (3,4,5-F)Phe or (2,3,4,5,6-F)Phe;

or a pharmaceutically acceptable salt thereof.

7. (original) A compound according to claim 6, wherein:

A^3 is Ile or is deleted;

A^4 is Lys or is deleted;

A^6 is Glu or is deleted;

A^7 is Ala or is deleted;

A^9 is Gly or is deleted;

A^{10} is Glu or is deleted;

A^{11} is Asp or is deleted;

A^{12} is Ala or is deleted;

A^{13} is Ser or is deleted;

A^{14} is Pro or is deleted;

A^{15} is Glu or is deleted;

A^{16} is Glu or is deleted;

A^{17} is Leu or is deleted;

A^{18} is Asn or is deleted;

A^{19} is Arg or is deleted;

A^{20} is Tyr or is deleted;

A^{21} is Tyr or is deleted;

A^{22} is Ala, Aib, or A5c, or is deleted;

A^{23} is Ser or is deleted;

A^{24} is Leu or A6c;

A^{25} is Arg;

A^{26} is His, 2Pal, D2Pal, 3Pal, 4Pal, or Taz;

A^{27} is Tyr or (3,4,5-F)Phe;

A^{28} is Leu, or A6c;

A^{29} is Asn;

A^{30} is Leu or A6c;

A^{31} is Val, Leu, A5c or A6c;

A^{32} is Thr;

A^{33} is Arg;

A^{34} is Gln; and

A^{36} is Tyr;

or a pharmaceutically acceptable salt thereof.

8. (original) A compound according to claim 6, wherein said compound is according to the formula:

((2,3,4,5,6-F)Phe^{20})hPYY(3-36)NH_2; (SEQ ID NO. 31)

((2,3,4,5,6-F)Phe^{21})hPYY(3-36)NH_2; (SEQ ID NO. 32)

Ac-((2,3,4,5,6-F)Phe^{26})hPYY(22-36)NH_2; (SEQ ID NO. 33)

Ac-((2,3,4,5,6-F)Phe^{26})hPYY(24-36)NH_2; (SEQ ID NO. 34)

((2,3,4,5,6-F)Phe^{26})hPYY(3-36)NH_2; (SEQ ID NO. 35)

Ac-((2,3,4,5,6-F)Phe^{27})hPYY(22-36)NH_2; (SEQ ID NO. 36)

Ac-((2,3,4,5,6-F)Phe^{27})hPYY(24-36)NH_2; (SEQ ID NO. 37)

((2,3,4,5,6-F)Phe^{27})hPYY(3-36)NH_2; (SEQ ID NO. 38)

Ac-((2,3,4,5,6-F)Phe^{36})hPYY(22-36)NH_2; (SEQ ID NO. 39)

Ac-((2,3,4,5,6-F)Phe^{36})hPYY(24-36)NH_2; (SEQ ID NO. 40)

((2,3,4,5,6-F)Phe^{36})hPYY(3-36)NH_2; (SEQ ID NO. 41)

((3,4,5-F)Phe^{20})hPYY(3-36)NH_2; (SEQ ID NO. 42)

((3,4,5-F)Phe^{21})hPYY(3-36)NH_2; (SEQ ID NO. 43)

Ac-((3,4,5-F)Phe^{26})hPYY(22-36)NH_2; (SEQ ID NO. 44)

Ac-((3,4,5-F)Phe^{26})hPYY(24-36)NH_2; (SEQ ID NO. 45)

((3,4,5-F)Phe^{26})hPYY(3-36)NH_2; (SEQ ID NO. 46)

Ac- ((3,4,5-F)Phe^{27})hPYY(22-36)NH_2; (SEQ ID NO. 15)

Ac-((3,4,5-F)Phe^{27})hPYY(24-36)NH_2; (SEQ ID NO. 47)

((3,4,5-F)Phe^{27})hPYY(3-36)NH_2; (SEQ ID NO. 12)

Ac-((3,4,5-F)Phe^{36})hPYY(22-36)NH_2; (SEQ ID NO. 48)

Ac-((3,4,5-F)Phe^{36})hPYY(24-36)NH_2; (SEQ ID NO. 49)

((3,4,5-F)Phe^{36})hPYY(3-36)NH_2; (SEQ ID NO. 50)

Ac-(D2Pal^{26})hPYY(22-36)NH_2; (SEQ ID NO. 26)

Ac-(2Pal^{26})hPYY(22-36)NH_2; (SEQ ID NO. 27)

Ac-(2Pal^{26}, Leu^{31})hPPY(24-36)NH_2; (SEQ ID NO. 18)

Ac-(3Pal^{26})hPYY(22-36)NH_2; (SEQ ID NO. 14)

(3Pal^{26})hPYY(3-36)NH_2; (SEQ ID NO. 5)

Ac-(3Pal^{26}, Leu^{31})hPPY(24-36)NH_2; (SEQ ID NO. 16)

Ac-(4Pal^{26})hPYY(22-36)NH_2; (SEQ ID NO. 13)

Ac-(4Pal^{26}, Leu^{31})hPPY(24-36)NH_2; (SEQ ID NO. 17)

Ac-(A5c^{22})hPYY(22-36)NH_2 (SEQ ID NO. 4)

Ac-(A5c^{31})hPYY(22-36)NH_2; (SEQ ID NO. 24)

Ac-(A5c^{31})hPYY(24-36)NH_2; (SEQ ID NO. 51)

(A5c^{31})hPYY(3-36)NH_2 (SEQ ID NO. 3)

(A6c^{10})hPYY(3-36)NH_2; (SEQ ID NO. 52)

(A6c^{11})hPYY(3-36)NH_2; (SEQ ID NO. 53)

(A6c^{12})hPYY(3-36)NH_2; (SEQ ID NO. 54)

(A6c^{13})hPYY(3-36)NH_2; (SEQ ID NO. 55)

(A6c^{15})hPYY(3-36)NH_2; (SEQ ID NO. 56)

(A6c^{16})hPYY(3-36)NH_2; (SEQ ID NO. 57)

(A6c^{17})hPYY(3-36)NH_2; (SEQ ID NO. 58)

(A6c^{18})hPYY(3-36)NH_2; (SEQ ID NO. 59)

(A6c^{20})hPYY(3-36)NH_2; (SEQ ID NO. 60)

(A6c^{21})hPYY(3-36)NH_2; (SEQ ID NO. 61)

Ac-(A6c^{22})hPYY(22-36)NH_2; (SEQ ID NO. 62)

(A6c^{22})hPYY(3-36)NH_2;	(SEQ ID NO. 63)
Ac-(A6c^{24})hPYY(22-36)NH_2;	(SEQ ID NO. 25)
Ac-(A6c^{24})hPYY(24-36)NH_2;	(SEQ ID NO. 64)
(A6C^{24})hPYY(3-36)NH_2;	(SEQ ID NO. 10)
Ac-(A6c^{24}, Leu^{31})hPYY(24-36)NH_2;	(SEQ ID NO. 28)
Ac-(A6c^{27})hPYY(22-36)NH_2;	(SEQ ID NO. 65)
Ac-(A6c^{27})hPYY(24-36)NH_2;	(SEQ ID NO. 66)
(A6c^{27})hPYY(3-36)NH_2;	(SEQ ID NO. 67)
Ac-(A6c^{28})hPYY(22-36)NH_2;	(SEQ ID NO. 23)
Ac-(A6c^{28})hPYY(24-36)NH_2;	(SEQ ID NO. 68)
(A6c^{28})hPYY(3-36)NH_2;	(SEQ ID NO. 8)
Ac-(A6c^{28}, Leu^{31})hPYY(24-36)NH_2;	(SEQ ID NO. 29)
Ac-(A6c^{29})hPYY(22-36)NH_2;	(SEQ ID NO. 69)
Ac-(A6c^{29})hPYY(24-36)NH_2;	(SEQ ID NO. 70)
(A6c^{29})hPYY(3-36)NH_2;	(SEQ ID NO. 71)
(A6c^{3})hPYY(3-36)NH_2;	(SEQ ID NO. 72)
Ac-(A6c^{30})hPYY(22-36)NH_2;	(SEQ ID NO. 22)
Ac-(A6c^{30})hPYY(24-36)NH_2;	(SEQ ID NO. 73)
(A6c^{30})hPYY(3-36)NH_2;	(SEQ ID NO. 9)
Ac-(A6c^{31})hPYY(22-36)NH_2;	(SEQ ID NO. 21)
Ac-(A6c^{31})hPYY(24-36)NH_2;	(SEQ ID NO. 30)
(A6c^{31})hPYY(3-36)NH_2;	(SEQ ID NO. 74)
Ac-(A6c^{32})hPYY(22-36)NH_2;	(SEQ ID NO. 75)
Ac-(A6c^{32})hPYY(24-36)NH_2;	(SEQ ID NO. 76)
(A6c^{32})hPYY(3-36)NH_2;	(SEQ ID NO. 77)
(A6c^{6})hPYY(3-36)NH_2;	(SEQ ID NO. 78)
(A6c^{7})hPYY(3-36)NH_2;	(SEQ ID NO. 79)
(A6c^{9})hPYY(3-36)NH_2;	(SEQ ID NO. 80)
(Act^{12})hPYY(3-36)NH_2;	(SEQ ID NO. 81)
(Act^{13})hPYY(3-36)NH_2;	(SEQ ID NO. 82)
Ac-(Act^{23})hPYY(22-36)NH_2;	(SEQ ID NO. 83)
(Act^{23})hPYY(3-36)NH_2;	(SEQ ID NO. 84)
Ac-(Act^{32})hPYY(22-36)NH_2;	(SEQ ID NO. 85)
Ac-(Act^{32})hPYY(24-36)NH_2;	(SEQ ID NO. 86)

$(Act^{32})hPYY(3-36)NH_2$;	(SEQ ID NO. 87)
$(Act^{7})hPYY(3-36)NH_2$;	(SEQ ID NO. 88)
Ac-$(Aib^{22})hPYY(22-36)NH_2$;	(SEQ ID NO. 89)
$(Aib^{22})hPYY(3-36)NH_2$;	(SEQ ID NO. 11)
$(Apc^{19})hPYY(3-36)NH_2$;	(SEQ ID NO. 90)
Ac-$(Apc^{25})hPYY(22-36)NH_2$;	(SEQ ID NO. 91)
Ac-$(Apc^{25})hPYY(24-36)NH_2$;	(SEQ ID NO. 92)
$(Apc^{25})hPYY(3-36)NH_2$;	(SEQ ID NO. 93)
Ac-$(Apc^{26})hPYY(22-36)NH_2$;	(SEQ ID NO. 94)
Ac-$(Apc^{26})hPYY(24-36)NH_2$;	(SEQ ID NO. 95)
$(Apc^{26})hPYY(3-36)NH_2$;	(SEQ ID NO. 96)
Ac-$(Apc^{33})hPYY(22-36)NH_2$;	(SEQ ID NO. 97)
Ac-$(Apc^{33})hPYY(24-36)NH_2$;	(SEQ ID NO. 98)
$(Apc^{33})hPYY(3-36)NH_2$;	(SEQ ID NO. 99)
Ac-$(Apc^{34})hPYY(22-36)NH_2$;	(SEQ ID NO. 100)
Ac-$(Apc^{34})hPYY(24-36)NH_2$;	(SEQ ID NO. 101)
$(Apc^{34})hPYY(3-36)NH_2$;	(SEQ ID NO. 102)
Ac-$(Apc^{35})hPYY(22-36)NH_2$;	(SEQ ID NO. 103)
Ac-$(Apc^{35})hPYY(24-36)NH_2$;	(SEQ ID NO. 104)
$(Apc^{35})hPYY(3-36)NH_2$;	(SEQ ID NO. 7)
Ac-$(Apc^{36})hPYY(22-36)NH_2$;	(SEQ ID NO. 105)
Ac-$(Apc^{36})hPYY(24-36)NH_2$;	(SEQ ID NO. 106)
$(Apc^{36})hPYY(3-36)NH_2$;	(SEQ ID NO. 107)
$(Apc^{4})hPYY(3-36)NH_2$;	(SEQ ID NO. 108)
$(Taz^{26})hPYY(3-36)NH_2$;	(SEQ ID NO. 6)
Ac-$(Taz^{26})hPYY(22-36)NH_2$;	(SEQ ID NO. 20)
Ac-$(Taz^{26}, Leu^{31})hPPY(24-36)NH_2$;	(SEQ ID NO. 19)

or a pharmaceutically acceptable salt thereof.

9. (currently amended) A compound according to claim 8, wherein said compound is according to the formula:

$[A5C^{31}]hPYY(3-36)NH_2$	(SEQ ID NO. 3)
Ac-$[A5C^{22}]hPYY(22-36)NH_2$	(SEQ ID NO. 4)
$[3Pal^{26}]hPYY(3-36)NH_2$;	(SEQ ID NO. 5)

[Taz^{26}]hPYY(3-36)NH_2;	(SEQ ID NO. 6)
[Apc^{35}]hPYY(3-36)NH_2;	(SEQ ID NO. 7)
[$A6C^{28}$]hPYY(3-36)NH_2;	(SEQ ID NO. 8)
[$A6C^{30}$]hPYY(3-36)NH_2;	(SEQ ID NO. 9)
[$A6C^{24}$]hPYY(3-36)NH_2;	(SEQ ID NO. 10)
[Aib^{22}]hPYY(3-36)NH_2;	(SEQ ID NO. 11)
[((3,4,5-F)Phe)^{27}]hPYY(3-36)NH_2;	(SEQ ID NO. 12)
Ac-[$4Pal^{26}$]hPYY(22-36)NH_2;	(SEQ ID NO. 13)
Ac-[$3Pal^{26}$]hPYY(22-36)NH_2;	(SEQ ID NO. 14)
Ac-[((3,4,5-F)Phe)^{27}]hPYY(22-36)NH_2;	(SEQ ID NO. 15)
Ac-($3Pal^{26}$, Leu^{31})hPPY(24-36)NH_2;	(SEQ ID NO. 16)
Ac-($4Pal^{26}$, Leu^{31})hPPY(24-36)NH_2;	(SEQ ID NO. 17)
Ac-($2Pal^{26}$, Leu^{31})hPPY(24-36)NH_2;	(SEQ ID NO. 18)
Ac-(Taz^{26}, Leu^{31})hPPY(24-36)NH_2;	(SEQ ID NO. 19)
Ac-[Taz^{26}]hPYY(22-36)NH_2;	(SEQ ID NO. 20)
Ac-[$A6c^{31}$]hPYY(22-36)NH_2;	(SEQ ID NO. 21)
Ac-[$A6c^{30}$]hPYY(22-36)NH_2;	(SEQ ID NO. 22)
Ac-[$A6c^{28}$]hPYY(22-36)NH_2;	(SEQ ID NO. 23)
Ac-[$A5c^{31}$]hPYY(22-36)NH_2;	(SEQ ID NO. 24)
Ac-[$A6C^{24}$]hPYY(22-36)NH_2;	(SEQ ID NO. 25)
Ac-[$D2Pal^{26}$]hPYY(22-36)NH_2;	(SEQ ID NO. 26)
Ac-[$2Pal^{26}$]hPYY(22-36)NH_2;	(SEQ ID NO. 27)
Ac-[$A6C^{24}$, Leu^{31}]hPYY(24-36)NH_2;	(SEQ ID NO. 28)
Ac-[$A6C^{28}$, Leu^{31}]hPYY(24-36)NH_2;	(SEQ ID NO. 29)
Ac-[$A6C^{31}$]hPYY(24-36)NH_2;	(SEQ ID NO. 30)
Ac-($A6c^{24}$)hPYY(24-36)NH_2;	(SEQ ID NO. 64)

or a pharmaceutically acceptable salt thereof.

10. (original) A compound according to claim 9, wherein said compound is:

[$A5C^{31}$]hPYY(3-36)NH_2	(SEQ ID NO. 3)
[$3Pal^{26}$]hPYY(3-36)NH_2;	(SEQ ID NO. 5)
[Taz^{26}]hPYY(3-36)NH_2;	(SEQ ID NO. 6)
[$A6C^{28}$]hPYY(3-36)NH_2;	(SEQ ID NO. 8)
[$A6C^{24}$]hPYY(3-36)NH_2;	(SEQ ID NO. 10)

[Aib^{22}]hPYY(3-36)NH_2; (SEQ ID NO. 11)

[((3,4,5-F)Phe)^{27}]hPYY(3-36)NH_2; (SEQ ID NO. 12)

Ac-[4Pal^{26}]hPYY(22-36)NH_2; (SEQ ID NO. 13)

Ac-[3Pal^{26}]hPYY(22-36)NH_2; (SEQ ID NO. 14)

Ac-(3Pal^{26}, Leu^{31})hPPY(24-36)NH_2; (SEQ ID NO. 16)

Ac-(4Pal^{26}, Leu^{31})hPPY(24-36)NH_2; (SEQ ID NO. 17)

or a pharmaceutically acceptable salt thereof.

11. (original) A compound according to claim 9, wherein said compound is:

[A5C^{31}]hPYY(3-36)NH_2 (SEQ ID NO. 3)

[3Pal^{26}]hPYY(3-36)NH_2; (SEQ ID NO. 5)

[Taz^{26}]hPYY(3-36)NH_2; (SEQ ID NO. 6)

[Apc^{35}]hPYY(3-36)NH_2; (SEQ ID NO. 7)

[A6C^{28}]hPYY(3-36)NH_2; (SEQ ID NO. 8)

[A6C^{24}]hPYY(3-36)NH_2; (SEQ ID NO. 10)

[Aib^{22}]hPYY(3-36)NH_2; (SEQ ID NO. 11)

Ac-[4Pal^{26}]hPYY(22-36)NH_2; (SEQ ID NO. 13)

Ac-[3Pal^{26}]hPYY(22-36)NH_2; (SEQ ID NO. 14)

Ac-(3Pal^{26}, Leu^{31})hPPY(24-36)NH_2; (SEQ ID NO. 16)

Ac-(4Pal^{26}, Leu^{31})hPPY(24-36)NH_2; (SEQ ID NO. 17)

or a pharmaceutically acceptable salt thereof.

12. (currently amended) A compound according to claim 9, wherein said compound is:

[A5C^{31}]hPYY(3-36)NH_2 (SEQ ID NO. 3)

[3Pal^{26}]hPYY(3-36)NH_2; (SEQ ID NO. 5)

[A6C^{28}]hPYY(3-36)NH_2; (SEQ ID NO. 8)

[A6C^{24}]hPYY(3-36)NH_2; (SEQ ID NO. 10)

Ac-[4Pal^{26}]hPYY(22-36)NH_2; (SEQ ID NO. 13)

Ac-(A6c^{24})hPYY(24-36)NH_2; (SEQ ID NO. 64)

or a pharmaceutically acceptable salt thereof.

13. (currently amended) A pharmaceutical composition comprising a compound according to claim 1 ~~any one of claims 1 - 12~~, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

14. (currently amended) A method of decreasing excess intestinal water and electrolyte secretion in a mammal in need thereof, said method comprising administering to said mammal an effective amount of a compound according to claim 1 ~~any one of claims 1 – 12~~, or a pharmaceutically acceptable salt thereof.

15. (currently amended) A method of regulating cell proliferation in a mammal in need thereof, said method comprising administering to said mammal an effective amount of a compound according to claim 1~~any one of claims 1 – 12~~, or a pharmaceutically acceptable salt thereof.

16. (original) A method of claim 15, wherein said cell is a gastrointestinal cell.

17. (original) A method of claim 15, wherein said cell is an epithelial cell.

18. (currently amended) A method of augmenting nutrient transport in a mammal in need thereof, said method comprising administering to said mammal an effective amount of a compound according to claim 1 ~~any one of claims 1 – 12~~, or a pharmaceutically acceptable salt thereof.

19. (currently amended) A method of regulating lipolysis in a mammal in need thereof, said method comprising administering to said mammal an effective amount of a compound according to claim 1~~any one of claims 1 – 12~~, or a pharmaceutically acceptable salt thereof.

20. (currently amended) A method of regulating blood flow in a mammal in need thereof, said method comprising administering to said mammal an effective amount of a compound according to claim 1~~any one of claims 1 – 12~~, or a pharmaceutically acceptable salt thereof.

21. (currently amended) A method of facilitating weight loss, appetite decrease, weight maintenance, treating obesity, treating diabetes, treating complications of diabetes including retinopathy, or treating cardiovascular disorders in a mammal in need thereof, said method comprising administering to said mammal an effective amount of a compound according to claim 1~~any one of claims 1 – 12~~, or a pharmaceutically acceptable salt thereof.

22. (original) A method according to claim 21, wherein excessive weight is a contributing factor to a disease or condition including hypertension, diabetes, dyslipidemia, cardiovascular disease, gall stones, osteoarthritis and cancers.

23. (original) A method according to claim 22, wherein said facilitation of weight loss reduces the likelihood of such diseases or conditions or where said facilitation of weight loss comprises at least part of a treatment for such diseases or conditions.

24. (currently amended) A method of antagonizing the effects of PYY(3-36) in a mammal in need thereof, said method comprising administering to said mammal an effective amount of a compound according to claim 1~~any one of claims 1 – 12~~, or a pharmaceutically acceptable salt thereof, wherein said compound is a PYY antagonist.

25. (original) A method according to claim 24, wherein said antagonist effects in said mammal comprise facilitating weight gain, facilitating maintenance in weight, and/or facilitating appetite increase.

26. (original) A method according to claim 25, wherein said facilitating weight gain, facilitating maintenance in weight, and/or facilitating appetite increase is indicated in a mammal having a disease or disorder, or under going a treatment, accompanied by weight loss.

27. (original) A method according to claim 26, wherein said diseases or disorders accompanied by weight loss include anorexia, bulimia, cancer cachexia, AIDS, wasting, cachexia, and wasting in frail elderly.

28. (original) A method according to claim 26, wherein said treatment accompanied by weight loss comprises chemotherapy, radiation therapy, temporary or permanent immobilization, or dialysis.